Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Andrea Cortegiani, Mariachiara Ippolito, Massimiliano Greco, et al.
Pulmonology (2020) Vol. 27, Iss. 1, pp. 52-66
Open Access | Times Cited: 180

Showing 1-25 of 180 citing articles:

Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects
Dina Visca, Ong C, Simon Tiberi, et al.
Pulmonology (2021) Vol. 27, Iss. 2, pp. 151-165
Open Access | Times Cited: 282
The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives
José Laerte Boechat, Inês Chora, António Morais, et al.
Pulmonology (2021) Vol. 27, Iss. 5, pp. 423-437
Open Access | Times Cited: 185
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 9
Open Access | Times Cited: 134
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis
Muhammad Aziz, Hossein Haghbin, Emad Abu Sitta, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 3, pp. 1620-1630
Closed Access | Times Cited: 104
Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from the In-Silico World
Muhammad Fayyaz ur Rehman, Shahzaib Akhter, Aima Iram Batool, et al.
Antibiotics (2021) Vol. 10, Iss. 8, pp. 1011-1011
Open Access | Times Cited: 64
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, et al.
Cochrane library (2021)
Open Access | Times Cited: 64
Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence
Elena Campione, Caterina Lanna, Terenzio Cosio, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 20, pp. 10985-10985
Open Access | Times Cited: 61
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
Corrado Pelaia, Cecilia Calabrese, Eugenio Garofalo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3059-3059
Open Access | Times Cited: 54
The role of IL-6 in coronavirus, especially in COVID-19
Xinyi Wang, Guozheng Tang, Yuchen Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 54
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY
Denyse Lutchmansingh, Melissa P. Knauert, Danielle Antin‐Ozerkis, et al.
CHEST Journal (2020) Vol. 159, Iss. 3, pp. 949-958
Open Access | Times Cited: 62
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
Avi Kaye, Robert D. Siegel
PeerJ (2020) Vol. 8, pp. e10322-e10322
Open Access | Times Cited: 58
Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity
Anna Lucia Fedullo, Antonio Schiattarella, Maddalena Morlando, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1213-1213
Open Access | Times Cited: 48
Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019
Mohamed Fizur Nagoor Meeran, Hayate Javed, Charu Sharma, et al.
Heliyon (2021) Vol. 7, Iss. 2, pp. e05990-e05990
Open Access | Times Cited: 48
Different disease, same challenges: Social determinants of tuberculosis and COVID-19
Raquel Duarte, Ana Aguiar, Maria João Pinto, et al.
Pulmonology (2021) Vol. 27, Iss. 4, pp. 338-344
Open Access | Times Cited: 46
Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study
Roberto Tonelli, Lara Pisani, Luca Tabbì, et al.
Pulmonology (2021) Vol. 28, Iss. 3, pp. 181-192
Open Access | Times Cited: 45
Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
Zeynab Mohamadi Yarijani, Houshang Najafi
Biomedicine & Pharmacotherapy (2021) Vol. 142, pp. 111966-111966
Open Access | Times Cited: 41
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
Su‐Yeon Yu, Dae-Hyup Koh, Miyoung Choi, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1154-1165
Open Access | Times Cited: 32
Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis
Alejandro Piscoya, Angela Parra del Riego, Renato Cerna-Viacava, et al.
PLoS ONE (2022) Vol. 17, Iss. 6, pp. e0269368-e0269368
Open Access | Times Cited: 29
Immunomodulatory approaches in managing lung inflammation in COVID‐19: A double‐edge sword
Geetika Verma, Manish Dhawan, AbdulRahman A. Saied, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 18
Identification of antiviral phytochemicals from cranberry as potential inhibitors of SARS-CoV-2 main protease (Mpro)
Jisha Pillai U, L. Cherian, Khushman Taunk, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129655-129655
Closed Access | Times Cited: 6
Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection
Bryce M. Warner, Robert Vendramelli, Amrit S. Boese, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0316952-e0316952
Open Access
Novel coronavirus disease (COVID-19) pandemic: A recent mini review
Muhammad Fayyaz ur Rehman, Chaudhary Fariha, Aqsa Anwar, et al.
Computational and Structural Biotechnology Journal (2020) Vol. 19, pp. 612-623
Open Access | Times Cited: 46
Predictors of Mortality in Critically Ill COVID‐19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy
Višeslav Popadić, Slobodan Klašnja, Nataša Milić, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 36
COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges
Gholam Reza Sivandzadeh, Hassan Askari, Ali Reza Safarpour, et al.
World Journal of Clinical Cases (2021) Vol. 9, Iss. 22, pp. 6178-6200
Open Access | Times Cited: 36
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 4, pp. 1837-1885
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top